Clinuvel Pharmaceuticals Ltd CUV
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CUV is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- A$14.86
- Day Range
- A$14.76–15.07
- 52-Week Range
- A$12.96–21.45
- Bid/Ask
- A$14.76 / A$15.12
- Market Cap
- A$744.54 Mil
- Volume/Avg
- 45,805 / 139,291
Key Statistics
- Price/Earnings (Normalized)
- 18.92
- Price/Sales
- 9.67
- Dividend Yield (Trailing)
- 0.34%
- Dividend Yield (Forward)
- 0.34%
- Total Yield
- 0.34%
Company Profile
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 16
- Website
- https://www.clinuvel.com
Competitors
Valuation
|
Metric
|
CUV
|
AVH
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.92 | — | 14.94 |
Price/Book Value | 4.17 | 4.65 | 36.12 |
Price/Sales | 9.67 | 4.48 | 5.34 |
Price/Cash Flow | 18.59 | — | 15.44 |
Price/Earnings
CUV
AVH
ABBV
Financial Strength
|
Metric
|
CUV
|
AVH
|
ABBV
|
|---|---|---|---|
Quick Ratio | 6.38 | 7.35 | 0.72 |
Current Ratio | 6.86 | 7.88 | 0.94 |
Interest Coverage | 11.03 | −30.10 | 3.95 |
Quick Ratio
CUV
AVH
ABBV
Profitability
|
Metric
|
CUV
|
AVH
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 19.77% | −37.61% | 14.14% |
Return on Equity (Normalized) | 23.18% | −50.88% | 172.29% |
Return on Invested Capital (Normalized) | 22.09% | −44.09% | 27.87% |
Return on Assets
CUV
AVH
ABBV
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gyrkwpfjtv | Czvk | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mwnpkxzdz | Bxtgvml | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mlymbhcx | Bvlbbb | $103.7 Bil | |
MRNA
| Moderna Inc | Djmnnjjx | Tlsgh | $47.9 Bil | |
ARGX
| argenx SE ADR | Xnndvfm | Vghj | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Pbpztkn | Pcx | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pgshrzmjz | Lcsss | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gzqnhxq | Chprlfg | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Glvynwfcbc | Xspnld | $12.8 Bil | |
INCY
| Incyte Corp | Bcmmwnmw | Pskxmz | $12.1 Bil |